Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Equity Average (2020 - 2025)

Historic Equity Average for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $333.8 million.

  • Tarsus Pharmaceuticals' Equity Average rose 3633.92% to $333.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.8 million, marking a year-over-year increase of 3633.92%. This contributed to the annual value of $210.8 million for FY2024, which is 811.36% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Equity Average stood at $333.8 million, which was up 3633.92% from $337.5 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Equity Average ranged from a high of $337.5 million in Q2 2025 and a low of $158.0 million during Q1 2022
  • Over the past 5 years, Tarsus Pharmaceuticals' median Equity Average value was $197.8 million (recorded in 2022), while the average stood at $217.6 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Equity Average soared by 207811.3% in 2021 and then crashed by 1479.23% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Equity Average stood at $172.9 million in 2021, then increased by 14.36% to $197.8 million in 2022, then rose by 3.82% to $205.3 million in 2023, then increased by 12.51% to $231.0 million in 2024, then skyrocketed by 44.52% to $333.8 million in 2025.
  • Its Equity Average stands at $333.8 million for Q3 2025, versus $337.5 million for Q2 2025 and $283.5 million for Q1 2025.